Matthew S Block, MD, PhD

  • 1105 Citations
  • 18 Scopus h-Index
19962020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Matthew S Block is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

DeLeon, T. T., Almquist, D. R., Kipp, B. R., Langlais, B. T., Mangold, A., Winters, J. L., Kosiorek, H. E., Joseph, R. W., Dronca, R. S., Block, M. S., McWilliams, R. R., Kottschade, L. A., Rumilla, K. M., Voss, J. S., Seetharam, M., Sekulic, A., Markovic, S. N. & Bryce, A. H., Jan 1 2020, In : PloS one. 15, 3, e0230306.

Research output: Contribution to journalArticle

Open Access
  • Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer

    Narasimhulu, D. M., McGree, M. E., Weaver, A. L., Jatoi, A., LeBrasseur, N. K., Glaser, G. E., Langstraat, C. L., Block, M. S. & Kumar, A., Jan 1 2020, (Accepted/In press) In : Gynecologic oncology.

    Research output: Contribution to journalArticle

  • HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

    Ren, Y., Cherukuri, Y., Wickland, D. P., Sarangi, V., Tian, S., Carter, J. M., Mansfield, A. S., Block, M. S., Sherman, M. E., Knutson, K. L., Lin, Y. & Asmann, Y. W., Jan 1 2020, In : OncoImmunology. 9, 1, 1744947.

    Research output: Contribution to journalArticle

    Open Access
  • Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

    Knutson, K. L., Block, M. S., Norton, N., Erskine, C. L., Hobday, T. J., Dietz, A. B., Padley, D., Gustafson, M. P., Puglisi-Knutson, D., Mangskau, T. K., Chumsri, S., Dueck, A. C., Karyampudi, L., Wilson, G. & Degnim, A. C., Mar 1 2020, In : Clinical Cancer Research. 26, 5, p. 1045-1053 9 p.

    Research output: Contribution to journalArticle

  • Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

    Zamarin, D., Walderich, S., Holland, A., Zhou, Q., Iasonos, A. E., Torrisi, J. M., Merghoub, T., Chesebrough, L. F., Mcdonnell, A. S., Gallagher, J. M., Li, Y., Hollmann, T. J., Grisham, R. N., Erskine, C. L., Block, M. S., Knutson, K. L., O'Cearbhaill, R. E., Aghajanian, C. & Konner, J. A., Jun 1 2020, In : Journal for ImmunoTherapy of Cancer. 8, 1

    Research output: Contribution to journalArticle

    Open Access